Skip to main content

Advertisement

SpringerLink
Log in

Photodynamic therapy for choroidal neovascularization

The Jules Gonin Lecture, Montreux, Switzerland, 1 September 2002

  • Club Jules Gonin
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Thomas EL, Langhofer M. Closure of experimental subretinal neovascular vessels with dihematoporphyrin either augmented argon green laser photocoagulation. Photochemistry Photobiology. 1987;46(5):881–886.

    Google Scholar 

  2. Kliman G, Puliafito C, Stern D, Borirakchanyavat S, Gregory W. Phthalocyanine photodynamic therapy: new strategy for closure of choroidal neovascularization. Lasers Surg. Med. 1994;15:2–10.

    Google Scholar 

  3. Nanda S, Hatchell D, Tiedeman J, et al. A new method of vascular occlusion. Arch. Ophthalmol. 1987;105:1121–1124.

    Google Scholar 

  4. Miller H, Miller B. Photodynamic therapy of subretinal neovascularization in the monkey eye. Arch. Ophthalmol. 1993;111:855–860.

    Google Scholar 

  5. Miller JW, Walsh AW, Kramer M, et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch. Ophthalmol. 1995;113:810–818.

    Google Scholar 

  6. Kramer M, Miller J, Michaud N, et al. Liposomal BPD Verteporfin photodynamic therapy: selective treatment of choroidal neovascularization in monkeys. Ophthalmology. 1996;103:427–438.

    Google Scholar 

  7. Husain D, Miller J, Michaud N, Connolly E, Flotte T, Gragoudas E. Intravenous infusion using liposomal benzoporphyrin derivative verteporfin for photodynamic therapy of experimental choroidal neovascularization. Arch. Ophthalmol. 1996;114(8):978–985.

    Google Scholar 

  8. Moulton RS, Walsh AW, Miller JW, et al. Response of retinal and choroidal vessels to photodynamic therapy using benzoporphyrin derivative monoacid. Invest. Ophthalmol. Vis. Sci. 1993;34:1169. Abstract.

    Google Scholar 

  9. Husain D, Kramer M, Kenney A, et al. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to seven weeks after treatment. Invest. Ophthalmol. Vis. Sci. 1999.

  10. Reinke M, Canakis C, Husain D, et al. Photodynamic therapy (PDT) retreatment of normal retina and choroid in the primate. Invest. Ophthalmol. Vis. Sci. 1997;38:S17.

    Google Scholar 

  11. Kramer M, Kenney A, Delori F, et al. Imaging of experimental choroidal neovascularization (CNV) using liposomal benzoporphyrin derivative monoacid (BPD-MA) angiography. Invest. Ophthalmol. Vis. Sci. 1995;36:S236.

    Google Scholar 

  12. Miller J, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration. Results of a single treatment in a phase 1 and 2 study. Arch. Ophthalmol. 1999;117:1161–1173.

    Google Scholar 

  13. Schmidt-Erfurth U, Miller J, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration. Results of a retreatments in a phase 1 and 2 study. Arch. Ophthalmol. 1999;117:1177–1187.

    Google Scholar 

  14. Sickenberg M, Schmidt-Erfurth U, Miller J, et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks and idiopathic causes. Arch. Ophthalmol. 2000;117:327–336.

    Google Scholar 

  15. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin (Visudyne TM) therapy of subfoveal choroidal neovascularization in age-related macular degeneration. One year results of two randomized clinical trials—TAP Report #1. Arch. Ophthalmol. 1999;117:1329–1345.

    Google Scholar 

  16. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year vision results of two randomized clinical trials. TAP Report # 2. Arch. Ophthalmol. 2001;119:198–207.

    Google Scholar 

  17. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. One-year results of a randomized clinical trial. VIP Report # 1. Ophthalmology. 2001;108:841–852.

    Google Scholar 

  18. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of "early-onset" and occult subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of a randomized clinical trial- VIP Report # 2. Am. J. Ophthalmol. 2002;131:541–560.

    Google Scholar 

  19. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration with Verteporfin. Guidelines for using verteporfin (Visudyne TM) in photodynamic therapy to treat choroidal neovascularization. Retina. 2002;22:6–18.

    Google Scholar 

  20. Miller JW, Adamis AP, Shima D, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol. 1994;145(3):574–584.

    Google Scholar 

  21. Pierce EA, Avery R, Foley E, Aiello L, Smith LEH. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc. Natl. Acad. Sci. USA. 1995;92:905–909.

    Google Scholar 

  22. Husain D, Ryan A, Cuthbertson R, et al. Vascular endothelial growth factor (VEGF) expression is correlated with choroidal neovascularization in a monkey model. Invest. Ophthalmol. Vis. Sci. 1997;38:S501.

    Google Scholar 

  23. Aiello L, Avery R, Arrigg P, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. NEJM. 1994;331(22):1480–1487.

    Google Scholar 

  24. Kvanta A, Algvere P, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci. 1996;37:1929–1934.

    Google Scholar 

  25. Krzystolik M, Afsahari M, Adamis A, et al. Intravitreal anti-VEGF Antibody Fragment (rhuFab VEGF) Prevents experimental choroidal neovascularization. Arch. Ophthalmol. 2002;120:143–152.

    Google Scholar 

  26. Gauthier D, Husain D, Kim I, et al. Safety and efficacy of intravitreal injection or rhuFabVEGF in combination with verteporfin PDT on experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2002.

  27. Renno R, Delori F, Holzer R, Gragoudas E, Miller J. Photodynamic therapy using Lu-Tex induces apoptosis in vitro, and its effect is potentiated by angiostatin in retinal capillary endothelial cells. Invest. Ophthalmol. Vis. Sci. 2000;41:3963–3971.

    Google Scholar 

  28. Terada Y, Zacks D, Connolly E, Michaud N, Gragoudas E, Miller J. Modified verteporfin photodynamic therapy (PDT); PDT combined with angiostatin in vitro and in vivo. Invest. Ophthalmol. Vis. Sci. 2002.

  29. Renno R, Terada Y, Haddadin M, Delori F, Gragoudas E, Miller J. Selective targeting of verteporfin to choroidal neovascularization mediated by a homing peptide to VEGF-R2. Invest. Ophthalmol. Vis. Sci. 2002.

  30. Zacks D, Ezra E, Terada Y, et al. Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: angiographic and histologic characterization. Invest. Ophthalmol. Vis. Sci. 2002;43:2384–2391.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Angiogenesis and Laser Laboratories, Retina Service, Department of Ophtalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA

    Joan W. Miller

Authors
  1. Joan W. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joan W. Miller.

Additional information

Financial disclosure: The Massachusetts Eye and Ear Infirmary has an ownership interest in two US patents directed to the use of verteporfin. In addition, the Massachusetts Eye and Ear Infirmary has an ownership interest in certain patent applications directed to the selective destruction of subretinal choroidal neovasculature for the treatment of macular degeneration and other disorders. Should the Massachusetts Eye and Ear Infirmary receive royalties or other financial remuneration as a result of these patents and patent applications, Dr. Miller would receive a share of the same in accordance with the Massachusetts Eye and Ear Infirmary's institutional patent policy and procedures, which includes royalty-sharing provisions

In addition, Dr. Miller is a consultant for Eyetech Pharmaceuticals

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miller, J.W. Photodynamic therapy for choroidal neovascularization. Graefe's Arch Clin Exp Ophthalmol 241, 258–262 (2003). https://doi.org/10.1007/s00417-003-0623-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-003-0623-y

Keywords

Search

Navigation